Yayın:
Novel benzo[b]xanthene derivatives: Bismuth(III) triflate-catalyzed one-pot synthesis, characterization, and acetylcholinesterase, glutathione S-transferase, and butyrylcholinesterase inhibitory properties

dc.contributor.authorTurhan, Kadir
dc.contributor.authorPektas, Begum
dc.contributor.authorTurkan, Fikret
dc.contributor.authorTugcu, Fatma T.
dc.contributor.authorTurgut, Zuhal
dc.contributor.authorTaslimi, Parham
dc.contributor.authorKaraman, Halide S.
dc.contributor.authorGulcin, Ilhami
dc.date.accessioned2026-06-27T14:30:23Z
dc.date.issued2020
dc.description.abstractIn this study, 3,4-dihydro-12-aryl-1H-benzo[b]xanthene-1,6,11-(2H,12H)trione compounds were obtained through one-pot condensation of various substituted aromatic aldehydes, 2-hydroxy-1,4-naphthoquinone, and dimedone in the presence of Bi(OTf)(3) as a green and reusable catalyst. The structural characterization of these novel substituted benzo[b]xanthenes was performed by spectroscopic methods, and their inhibitory actions against butyrylcholinesterase (BChE), acetylcholinesterase (AChE), and glutathione S-transferase (GST) were investigated. GST is an enzyme responsible for removing toxic molecules during Phase II reactions in the detoxification mechanism. The AChE and BChE enzymes, which are called cholinesterases, are among the enzymes that occur especially during dementia such as brain damage or Alzheimer's disease. Inhibition effects of the benzo[b]xanthene derivatives on AChE, BChE, and GST were found at the millimolar level. The best inhibitor for GST is compound 4a (31.18 +/- 6.13 mM), for AChE, it is compound 4d (28.16 +/- 3.46 mM), and for BChE, it is compound 4f (36.24 +/- 3.19 mM). Compound 4a inhibited the dimerization of GST subunits, and compounds 4d and 4f directly inhibited the catalytic activity by interacting with the catalytic active site or a related site of the AChE and BChE enzymes, respectively.en
dc.description.sponsorshipYildiz Teknik Universitesi [FYL-2017-3243]
dc.description.urihttps://doi.org/10.1002/ardp.202000030
dc.identifier.doi10.1002/ardp.202000030
dc.identifier.eissn1521-4184
dc.identifier.issn0365-6233
dc.identifier.issue8
dc.identifier.pubmed32452582
dc.identifier.urihttps://hdl.handle.net/20.500.14981/61410
dc.identifier.volume353
dc.identifier.wos000535239900001
dc.language.isoeng
dc.publisherWILEY-V C H VERLAG GMBH
dc.relation.ispartofARCHIV DER PHARMAZIE
dc.rightsopenAccess
dc.subjectacetylcholinesterase
dc.subjectenzyme inhibition
dc.subjectmolecular docking
dc.subjectspectrophotometry
dc.subjectsynthesis
dc.subjectEFFICIENT CATALYST
dc.subjectREUSABLE CATALYST
dc.subject3-COMPONENT SYNTHESIS
dc.subjectXANTHENE DERIVATIVES
dc.subjectHIGHLY EFFICIENT
dc.subjectHYDROGEN SULFATE
dc.subjectSOLVENT-FREE
dc.subjectBENZOXANTHENES
dc.subjectGREEN
dc.subjectWATER
dc.subjectPharmacology & Pharmacy
dc.subjectChemistry
dc.titleNovel benzo[b]xanthene derivatives: Bismuth(III) triflate-catalyzed one-pot synthesis, characterization, and acetylcholinesterase, glutathione S-transferase, and butyrylcholinesterase inhibitory properties
dc.typeArticle
dspace.entity.typePublication
local.import.sourceWOS

Dosyalar

Koleksiyonlar